Loading...
Market
What financial impact will MRT-6160 have on Novartis by end of 2025?
2
Resolution / Starting Odds
Revenue decrease due to MRT-6160 • 25%
Revenue increase due to MRT-6160 • 25%
No significant financial impact • 25%
MRT-6160 discontinued • 25%
Financial reports and press releases from Novartis
Story
Monte Rosa and Novartis Sign $150M Global License Agreement for MRT-6160 with $2.2B Milestone
Oct 28, 2024, 11:30 AM
Monte Rosa Therapeutics has announced a global license agreement with Novartis to advance T and B cell-modulating VAV1-directed molecular glue degraders. Novartis has committed $150 million upfront, with potential milestone payments that could exceed $2.2 billion, including $2.1 billion downstream. The deal aims to further develop Monte Rosa's MRT-6160, which is currently in Phase 1 trials. This agreement is part of Monte Rosa's broader strategy, which includes a recent collaboration with Roche to target previously undruggable cancer and neurological disease targets. Monte Rosa's CEO is Markus Warmuth, with Filip Janku as Chief Medical Officer and Jocelyn Castle as Chief Data and Information Officer. The upfront payment is half of Monte Rosa's market cap. Monte Rosa's platform/discovery engine is called QuEEN (Quantitative & Engineered Elimination of Neosubstrates).
View original story
Similar markets
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No significant increase • 25%
Up to $150 million • 25%
$150 million to $500 million • 25%
$500 million to $1 billion • 25%
Over $1 billion • 25%
Novartis outperforms competitors • 25%
Novartis performs equally as competitors • 25%
Novartis underperforms competitors • 25%
Stock performance is inconclusive • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Market share increases • 25%
Market share remains stable • 25%
Market share decreases • 25%
Market exit • 25%
Increases revenue by more than 5% • 25%
Increases revenue by up to 5% • 25%
No significant impact on revenue • 25%
Decreases revenue • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
Over $2 billion • 25%
Positive • 25%
Negative • 25%
Neutral • 25%
Not Reported • 25%
Positive impact • 33%
Neutral impact • 33%
Negative impact • 33%